Loading...
Market
What will be CFS's next major milestone announcement for ARC by 2025?
2
Commonwealth Fusion Systems•Massachusetts Institute of Technology•Chesterfield County•Virginia•Dominion Energy Virginia
Resolution / Starting Odds
Completion of Site Preparation • 25%
Start of Construction • 25%
First Major Funding Round • 25%
Partnership with New Stakeholders • 25%
Press releases from Commonwealth Fusion Systems
Story
CFS to Build ARC Fusion Plant in Chesterfield County, Virginia, Targeting 400 Megawatts by Early 2030s
Dec 17, 2024, 07:07 PM
Commonwealth Fusion Systems (CFS), a startup founded by scientists from the Massachusetts Institute of Technology, has announced plans to construct its first commercial fusion power plant, named ARC, in Chesterfield County, Virginia. The facility is expected to generate 400 megawatts of clean, firm, zero-carbon power and connect to the state's electrical grid in the early 2030s. The selection of the site followed an extensive evaluation of over 100 locations globally, with Virginia chosen for its economic growth, skilled workforce, and proximity to Washington, D.C. CFS is leasing the site from Dominion Energy Virginia, which will also provide development and technical expertise. This move marks a significant step towards realizing the potential of fusion energy, which promises cheap, abundant, and safe power without greenhouse gas emissions.
View original story
Similar markets
Partner with ExxonMobil • 25%
Partner with Shell • 25%
Partner with BP • 25%
No new major partner • 25%
New partnership • 25%
New product launch • 25%
New funding round • 25%
Other • 25%
Successful autonomous navigation in open waters • 25%
Integration with U.S. Navy's existing systems • 25%
Completion of first production-ready ASV • 25%
Other • 25%
Mapping of another insect's brain • 25%
Mapping of a mammalian brain • 25%
Development of a new simulation model • 25%
Other • 25%
Completion of site investigations • 25%
Submission of application under the ADVANCE Act • 25%
Approval of application under the ADVANCE Act • 25%
No major milestone achieved • 25%
Partnership • 25%
Protocol Upgrade • 25%
New Feature Launch • 25%
No Major Announcement • 25%
Cancer treatment • 25%
Battery development • 25%
Clean energy applications • 25%
Other • 25%
Safety Mechanism • 33%
AI Capabilities • 33%
Partnership or Funding • 34%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
New factory • 33%
New partnership • 33%
New product line • 34%